Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes-Reference-Cited by-同舟云学术

Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes

Published:2023-06-01 Issue:11-12 Volume:34 Page:554-566
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

West Cara¹,Federspiel Joel D.²^ORCID,Rogers Kara³,Khatri Arpana¹,Rao-Dayton Sheila⁴,Ocana Mireia Fernandez²,Lim Sean⁵,D'Antona Aaron Michael⁵,Casinghino Sandra³,Somanathan Suryanarayan¹^ORCID

Affiliation:

1. Pfizer, Inc., Rare Disease Research Unit, Cambridge, Massachusetts, USA

2. Pfizer, Inc., Drug Safety Research & Development, Andover, Massachusetts, USA

3. Pfizer, Inc., Drug Safety Research & Development, Groton, Connecticut, USA

4. Pfizer, Inc., Rare Disease Research Unit, Kit Creek, North Carolina, USA

5. Pfizer, Inc., Biomedicine Design, Cambridge, Massachusetts, USA.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2023.018

Reference41 articles.

1. Gene therapy enters the pharma market: The short story of a long journey

2. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

3. Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis

4. The clinical landscape for AAV gene therapies

5. Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of full and empty particles of adeno-associated virus vectors via a novel dual fluorescence-linked immunosorbent assay;Molecular Therapy - Methods & Clinical Development;2024-09

2. Adeno-Associated Virus Vectors—a Target of Cellular and Humoral Immunity—are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies;Human Gene Therapy;2024-08-28

3. Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer;Molecular Therapy;2024-07

4. Innate Immune Sensing of Adeno-Associated Virus Vectors;Human Gene Therapy;2024-07-01

5. Complement System Response to Adeno-Associated Virus Vector Gene Therapy;Human Gene Therapy;2024-07-01